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Commentary 
Although there is a large experience worldwide with 
the VAD in adults, and a proliferation of effective sup-
port systems, the pediatric experience remains relative-
ly limited. This is due to size and technical considera-
tions, but also to a perception that patients with 
complex congenital heart disease are unsuitable for 
univentricular support. Duncan and associates have 
provided evidence to the contrary, reporting their large 
pediatric experience with VAD and ECMO for cardiac 
and cardiopulmonary support. The clinical questions 
addressed are important for pediatric surgeons. The 
time frame and the similarities in patient populations 
and outcome invite commentary and comparison with 
experience at the Royal Children's Hospital. 
Since 1989, we have been using both VAD and 
ECMO,I-4 always employing centrifugal pumps. The 
centrifugal-pump VAD circuit is straightforward in 
concept and design, can be rapidly assembled and 
primed, and requires little technical attention. It is suit-
able for many cardiac arrest situations. In this format, 
the centrifugal pump is responsive to changes in the 
peripheral circulation, allowing fine tuning of inotrop-
ic drugs and vasodilators before weaning. The centrifu-
gal pump is probably safer than a roller pump for long-
term support outside the operating theater, since it 
generates constant pressure rather than flow. 
The majority of our postoperative support has been 
with VAD rather than ECMO systems. In practice, at 
least for intraoperative placement, adequacy of univen-
tricular support can be assessed by converting car-
diopulmonary bypass to partial left heart assist, and 
ceasing gas exchange across the oxygenator. The 
bypass circuit can then be converted to centrifugal-
pump VAD or ECMO, as appropriate, on the basis of 
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hemodynamics, oxygenation and carbon dioxide clear-
ance, and acid base status. 
We have used the VAD in 53 patients, median age 3.5 
months (range 2 days-19 years) and median weight 4 
kg (range 1.9-70 kg). Our results3-S were remarkably 
similar to those of Duncan and colleagues. The time on 
VAD was similar for survivors and nonsurvivors (P = 
.69), with a median of 75 hours. Thirty-eight of 53 chil-
dren were weaned from VAD (.72, CL = .57-.83) and 
24 of 53 were eventually discharged (.46, CL = .31-
.61). Kaplan-Meier survival probability at I year was 
.44 (CL = .31-.58). The post-weaning deaths reflected 
continued cardiac problems rather than specific VAD-
related complications. Age, weight, support time, car-
diopulmonary bypass time, ischemic time, univentricu-
lar anatomy, and timing of placement (intraoperative 
versus postoperative) were not strongly associated with 
survival probability. By comparison, of 40 patients sup-
ported with ECMO, 19 were weaned, 3 bridged to 
transplantation, and 19 eventually discharged from the 
hospital. Thus, although the weaning probability was 
better with VAD (.71 vs .48, P = .014), as in Boston the 
discharge probability was similar (.46 vs .48, P = 1.0). 
In interpreting these results, one must consider that 
most of the patients treated with a VAD could have 
been supported with ECMO, but the reverse would not 
generally apply. 
In the Boston experience, younger patients were 
more likely to be supported with ECMO than with 
VAD, because of the complexity of the underlying 
heart disease and technical considerations. In our own 
practice, 38 of 53 patients supported with a VAD 
weighed less than 6 kg.6 The probability of weaning 
was similar to that for the older patients (P = .07), but 
the I-year survival probability was poorer, primarily 
related to irreversible cardiac disease. The smallest 
patient in our series was a 19-day-old, 1.9-kg baby with 
Taussig-Bing anomaly and arch obstruction, who was 
placed on VAD support in the postoperative period dur-
ing a prolonged (1 hour) cardiac arrest and survived 
with no neurologic sequelae. As would be the case in 
Boston, we have been obliged to redefine the upper 
limit for reasonable resuscitation time in children in the 
era of circulatory support. 
Neither VAD nor ECMO in this format is eminently 
suitable for long-term support. Our longest successful 
supports have been 120 hours (ECMO) and 144 hours 
(VAD), although nonsurvivors were well supported 
metabolically for 384 hours (ECMO) and 428 hours 
(VAD). Our longest ECMO support for noncardiac 
indications has been 6 weeks. The usefulness of cen-
trifugal-pump VAD and ECMO as a bridge to trans-
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plantation will depend heavily on the immediate avail-
ability of suitable donor heat1s, a major problem in 
many parts of the world. A major limitation is our 
inability to wean most patients from ventilatory support 
during centrifugal-pump VAD and ECMO, mobilize 
them, and make them independent of the intensive care 
unit. 
There are two important questions to be addressed in 
analyzing this experience. First, do ECMO and VAD as 
reported herein adequately support the patient when 
cardiac function is compromised? The answer is dear-
ly yes, although not in every patient, and not indefi-
nitely. Second, does this type of support allow cardiac 
improvement to occur if improvement would not other-
wise have occurred in a given patient? This is a much 
more complicated question. To ask it another way: 
What is the effect of patient selection on outcome? As 
in most areas of cardiac surgery, it is profound. As a 
group, our VAD patients with anomalous origin of the 
left coronary artery from the pulmonary artery and 
those with transposition of the great arteries (especial-
ly patients with intact ventricular septum operated on 
after 3 weeks of age) had a significantly better survival 
probability than others (.91, CL = .59-l.0, P = .04).7 
The worst outcome was in patients with technically 
imperfect repairs, coagulopathy, and those with com-
plex cardiac anomalies that have an expected poor 
long-term outcome even if VAD and ECMO are not 
required. Perhaps this type of analysis of indications 
begs the question. In practice, if a reliable support 
device were available, almost any child accepted for a 
cardiac operation would be considered a candidate for 
support should the need arise. 
Centrifugal-pump VAD is not expensive technology. 
In our own unit, an additional nurse is required when 
ECMO is used, but not for VAD, during which the 
child's primary nurse also monitors the VAD circuit 
(with a perfusionist and cardiac surgeon on call). 
Consequently, VAD adds only approximately $250 per 
day to normal intensive care unit and hospital expenses, 
whereas ECMO adds 4 to 5 times that amount. 
The availability of paracorporeal pulsatile devices for 
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support of infants and children may render the cen-
trifugal pump system obsolete. Certainly there are sev-
eral very elegant systems in use in Europe at this time 
that are proving to be suitable for long-term support, 
even in very small infants. However, for short-term 
assistance, the costs involved may place these devices 
out of the reach of many units, especially those not 
actively involved in cardiac transplantation. 
The results with short-tenn mechanical support in 
Boston, Melbourne, and elsewhere strongly support 
continued application of this strategy for selected chil-
dren with severe cardiac failure. The simplicity and 
efficacy of centrifugal-pump VAD should place it in the 
armamentarium of all units prepared to undertake car-
diac operations in children. In the current era, decre-
ment in surgical mortality is very difficult to come by, 
and Duncan and associates have demonstrated a way of 
achieving this end. 
REFERENCES 
Tom R. Karl, MS, MD 
Victoria, Australia 
1. Karl TR, Horton SB. Mee RBB. Left heart assist for ischaemic 
postoperative ventricular dysfunction in an infant with anom-
alous left coronary artery. J Card Surg 1989;4:352-4. 
2. Karl TR, Horton SB, Sano ~, Mee RBB. Centrifugal pump left 
heart assist in pediatric cardiac surgery: indications, technique, 
and results. J Thorac Cardiovasc Surg 1991; 1 02:624-30. 
3. Karl TR. Pennington GD. Extracorporcal circulatory support in 
infants and children. Sem Thorac Cardiovasc Surg 1994;6: 154-
60. 
4. Cochrane AD, Horton A. Butt W, Skillington P. Karl TR, Mee 
RBB. Neonatal and paediatric extracorporeal membrane oxy-
genation. Aust Assoc J Card Thorae Surg 1992;1:17-22. 
5. Karl TR. Circulatory support in children. In: Hetzer R, Hennig E. 
Loebe M, editors. Mechanical circulatory support. Berlin: 
Springer; 1997. p. 7-20. 
6. Thuys CA, Mullaly RJ, HOlion SB, O'Connor EB, Cochrane AD, 
Brizard CP, et al. Centrifugal ventricular assist in children under 
6 kg. Eur J Cardiothorac Surg 1998:13:130-4. 
7. Cochrane AD. Coleman DM, Davis AD, Brizard CPR. Wolfe R. 
Karl TR. Excellent long-term functional outcome after an opera-
ti on for anomalous left coronary artery from the pulmonary 
artery. J Thorac Cardiovasc Surg 1998: In press. 
12/1/95921 
